255 related articles for article (PubMed ID: 24061646)
1. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.
Linker RA; Gold R
Curr Neurol Neurosci Rep; 2013 Nov; 13(11):394. PubMed ID: 24061646
[TBL] [Abstract][Full Text] [Related]
2. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.
Mori M; Ohashi T; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
Mult Scler J Exp Transl Clin; 2019; 5(2):2055217319852727. PubMed ID: 31218077
[TBL] [Abstract][Full Text] [Related]
4. New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo.
Ocaña MC; Bernal M; Yang C; Caro C; Domínguez A; Vu HS; Cárdenas C; García-Martín ML; DeBerardinis RJ; Quesada AR; Martínez-Poveda B; Medina MÁ
Commun Biol; 2023 Oct; 6(1):1084. PubMed ID: 37880317
[TBL] [Abstract][Full Text] [Related]
5. Emerging Therapeutic Applications for Fumarates.
Hoogendoorn A; Avery TD; Li J; Bursill C; Abell A; Grace PM
Trends Pharmacol Sci; 2021 Apr; 42(4):239-254. PubMed ID: 33618840
[TBL] [Abstract][Full Text] [Related]
6. Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19.
Timpani CA; Rybalka E
Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33375288
[TBL] [Abstract][Full Text] [Related]
7. Response to Letter to the Editor Regarding "Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis".
Lager B; Liseno J; Božin I; England SM; Shankar SL; Mendoza JP; Lewin JB
Neurol Ther; 2023 Dec; 12(6):2199-2203. PubMed ID: 37707704
[No Abstract] [Full Text] [Related]
8. Dimethyl fumarate for COVID-19.
Pathania YS
BMJ Support Palliat Care; 2021 Jun; ():. PubMed ID: 34172507
[No Abstract] [Full Text] [Related]
9. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
Fox RJ; Kita M; Cohan SL; Henson LJ; Zambrano J; Scannevin RH; O'Gorman J; Novas M; Dawson KT; Phillips JT
Curr Med Res Opin; 2014 Feb; 30(2):251-62. PubMed ID: 24131282
[TBL] [Abstract][Full Text] [Related]
10. Teriflunomide and its mechanism of action in multiple sclerosis.
Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H
Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824
[TBL] [Abstract][Full Text] [Related]
11. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
Burness CB; Deeks ED
CNS Drugs; 2014 Apr; 28(4):373-87. PubMed ID: 24623127
[TBL] [Abstract][Full Text] [Related]
12. Dimethyl fumarate for multiple sclerosis.
Xu Z; Zhang F; Sun F; Gu K; Dong S; He D
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414
[TBL] [Abstract][Full Text] [Related]
13. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.
Venci JV; Gandhi MA
Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625
[TBL] [Abstract][Full Text] [Related]
14. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.
Dubey D; Kieseier BC; Hartung HP; Hemmer B; Warnke C; Menge T; Miller-Little WA; Stuve O
Expert Rev Neurother; 2015 Apr; 15(4):339-46. PubMed ID: 25800129
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.
Sheikh SI; Nestorov I; Russell H; O'Gorman J; Huang R; Milne GL; Scannevin RH; Novas M; Dawson KT
Clin Ther; 2013 Oct; 35(10):1582-1594.e9. PubMed ID: 24139424
[TBL] [Abstract][Full Text] [Related]
16. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
Chen H; Assmann JC; Krenz A; Rahman M; Grimm M; Karsten CM; Köhl J; Offermanns S; Wettschureck N; Schwaninger M
J Clin Invest; 2014 May; 124(5):2188-92. PubMed ID: 24691444
[TBL] [Abstract][Full Text] [Related]
17. Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation.
McGuire VA; Ruiz-Zorrilla Diez T; Emmerich CH; Strickson S; Ritorto MS; Sutavani RV; Weiβ A; Houslay KF; Knebel A; Meakin PJ; Phair IR; Ashford ML; Trost M; Arthur JS
Sci Rep; 2016 Aug; 6():31159. PubMed ID: 27498693
[TBL] [Abstract][Full Text] [Related]
18. Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.
Bomprezzi R
Ther Adv Neurol Disord; 2015 Jan; 8(1):20-30. PubMed ID: 25584071
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
